Condition
KRAS P.G12C clinical trials and research
As of November 12, 2026, Find a Trial lists 5 KRAS P.G12C clinical trials that are recruiting, at sites in 10 countries (most in China (3), Spain (2), France (2)). By phase: Phase 2 (3), Phase 1/2 (2). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 10Countries
Newest KRAS P.G12C clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Evaluating JAB-21822 for pancreatic cancer and other solid tumors with a specific mutation | Phase 2 | Hefei, Anhui and 30 other locations | Recruiting | Aug 23, 2023 |
| Treatment of advanced lung cancer with sotorasib for patients with a specific KRAS mutation | Phase 2 | Lyon and 4 other locations | Recruiting | Nov 30, 2022 |
| Treatment for advanced solid tumors with a specific KRAS mutation | Phase 1/2 | Orange, California and 51 other locations | Recruiting | Jun 8, 2022 |
| Treatment of advanced lung cancer with Sotorasib for patients unable to undergo chemotherapy. | Phase 2 | Alicante, Alicante and 19 other locations | Recruiting | May 31, 2022 |
| Testing JAB-21822 and JAB-3312 in patients with advanced solid tumors and KRAS p.G12C mutation | Phase 1/2 | Hefei, Anhui and 26 other locations | Recruiting | Mar 21, 2022 |
All recruiting trials (5)
-
Evaluating JAB-21822 for pancreatic cancer and other solid tumors with a specific mutation
This study is testing a new drug called Glecirasib to see if it can help adults with advanced pancreatic cancer or other solid tumors that have a specific mutation and who haven't had success with other treatments.
-
Treatment of advanced lung cancer with sotorasib for patients with a specific KRAS mutation
This study is testing if a new drug called sotorasib can help people with advanced lung cancer who have a specific KRAS mutation and have already tried other treatments.
-
Treatment for advanced solid tumors with a specific KRAS mutation
This study is testing a new oral treatment called D3S-001 for people with advanced solid tumors that have a specific KRAS mutation to see if it works and is safe.
-
Treatment of advanced lung cancer with Sotorasib for patients unable to undergo chemotherapy.
This study is testing if a new drug called Sotorasib can help people with advanced lung cancer who can’t have chemotherapy live longer without their disease getting worse.
-
Testing JAB-21822 and JAB-3312 in patients with advanced solid tumors and KRAS p.G12C mutation
This study is testing a new combination of drugs, JAB-21822 and JAB-3312, to see if it helps people with advanced solid tumors that have a specific KRAS mutation.
Related topics
Quick answers
How many KRAS P.G12C clinical trials are recruiting right now?
5, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 10 countries. The most sites are in China (3 trials), Spain (2 trials), France (2 trials), Australia (1 trial), Germany (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 3, Phase 1/2: 2. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.